PlainPharmaWatch

CMS Open Payments · Program Year 2024

Nanovis LLC

Nanovis LLC reported $2,699,986.87 across General Payments, Research, and Ownership to 24 physicians and teaching hospitals across 37 transactions.

$2.7M
All-tracks total
37
Transactions
24
Recipients
+$35.1K
General Payments vs PY2023

Nanovis LLC reported $2,699,986.87 across all CMS Open Payments tracks (General + Research + Ownership) to 24 physicians and teaching hospitals in Program Year 2024 - ranking #388 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $47,018.78, averaging $112.5K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer nanovis-llc Nanovis LLC

$2.7M · #388/1,925 · 0.0% industry · PY2024

  • TOT $2.7M
  • RANK #388
  • SHARE 0.0%
  • TXN 37
  • RCP 24
  • CAT 3
  • GEN $47.0K
  • ΔGEN +$35.1K
  • TOP1 84.8%
  • PY 2024

Nearest volume peer: Tulsa Dental Products LLC ($2.7M)

Tulsa Dental Products LLC$2.7MNanovis LLC (this)$2.7MCVRx, Inc.$2.7MGalvanize Therapeutics, Inc$2.7MCalyxo, Inc.$2.7M
All-tracks payment totals near Nanovis LLC (CMS Open Payments PY2024)

Nanovis LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Nanovis LLC's CMS-reported General Payments increased by $35.1K (+294.7%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: NANOVIS LLCPY2023: NANOVIS LLCPY2024: Nanovis LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$11.9KPY2024$47.0K
PY2023
$11,911.69
PY2024
$47,018.78

What the Data Shows for Nanovis LLC

Rank #388 of 1,925 companies in CMS Open Payments for 2024 belongs to Nanovis LLC, which reported $2,699,986.87 across 37 transactions to 24 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $73.0K per transaction and $112.5K per recipient.

Of the 3 general-payment categories charted below, "Royalty or License" is the largest at $39.9K across 1 transactions, 84.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 3 types of general payments, Nanovis LLC's largest category was "Royalty or License" at $39.9K - 84.8% of General Payments.

How Nanovis LLC divides its payments

Ranked by total dollars reported per category

1. Royalty or License$39.9K2. Consulting Fee$5.8K3. Food and Beverage$1.3K
Payment Type Amount Transactions
Royalty or License $39.9K 1
Consulting Fee $5.8K 5
Food and Beverage $1.3K 18

Recipient Concentration in General Payments

The five largest recipient relationships account for $46,467.26 (98.8%) of $47,018.78 in this company's General Payments records across 12 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Nanovis LLC

The five named recipients with the highest reported General Payments from this company

Richard Rodgers$39.9KThomas J Webster$5.8KDouglas Pahl$321.27Todd Bonvallet$295.91Asif Shafiq$149.80
  1. 1

    Richard Rodgers

    $39,887.78 across 1 reported transactions

  2. 2

    Thomas J Webster

    $5,812.50 across 5 reported transactions

  3. 3

    Douglas Pahl

    $321.27 across 4 reported transactions

  4. 4

    Todd Bonvallet

    $295.91 across 2 reported transactions

  5. 5

    Asif Shafiq

    $149.80 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Nanovis LLC's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Nanovis LLC.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Nanovis LLC.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Nanovis LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.